Opicapone Treatment Initiation Open-Label Study

NCT04787965 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 239

Last updated 2022-11-28

No results posted yet for this study

Summary

This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with motor fluctuations

Conditions

  • Parkinson Disease

Interventions

DRUG

Opicapone

Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period

Sponsors & Collaborators

  • Neurocrine Biosciences

    lead INDUSTRY

Principal Investigators

  • Olga Klepitskaya, MD, FAAN · Neurocrine Biosciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-08-04
Completion
2022-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04787965 on ClinicalTrials.gov